Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 4:15:1607960.
doi: 10.3389/fonc.2025.1607960. eCollection 2025.

Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring

Affiliations
Review

Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring

Jiayi Sheng et al. Front Oncol. .

Abstract

Breast cancer is the most common malignant tumor and the leading cause of mortality among women worldwide. Triple-negative breast cancer (TNBC) is recognized as t the most aggressive form of breast cancer, with a poor prognosis and a high mortality rate within two years. The role of tumor markers in facilitating the early diagnosis, treatment, and monitoring of therapeutic efficacy and prognosis in TNBC is well-established. Currently, tissue biopsy remains the standard clinical method for determining tumor histology and staging. However, the invasive nature of tissue biopsy often leads to poor patient compliance, especially when repeated biopsies are required. In contrast, liquid biopsy offers several advantages: it is non-invasive, sample collection is straightforward, it can reflect the overall tumor burden and heterogeneity, and it allows for real-time monitoring. The markers primarily encompass circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs (miRNAs), long ncRNA (lncRNAs), exosome, and so forth. The present review aims to provide a comprehensive overview of the recent advancements and potential clinical applications of liquid biopsy technology in the context of TNBC.

Keywords: CTCs; CtDNA; TNBC; diagnostics; liquid biopsy; lncRNAs; miRNAs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram illustrating key circulating analytes used in TNBC liquid biopsy and their primary clinical utilities including Early diagnosis (screening and detection of initial disease), Prognostic prediction (risk stratification and outcome forecasting), and Evaluation of Treatment Efficacy (monitoring response to therapy and minimal residual disease).

Similar articles

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. (2022) 72:7–33. doi: 10.3322/caac.21708, PMID: - DOI - PubMed
    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. (2010) 363:1938–48. doi: 10.1056/NEJMra1001389, PMID: - DOI - PubMed
    1. Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. (2022) 17:181–204. doi: 10.1146/annurev-pathol-042420-093238, PMID: - DOI - PMC - PubMed
    1. Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, et al. Outcomes of triple-negative breast cancers (Tnbc) compared with non-tnbc: does the survival vary for all stages? World J Surg. (2016) 40:1362–72. doi: 10.1007/s00268-016-3422-4, PMID: - DOI - PubMed
    1. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer. (2012) 118:5463–72. doi: 10.1002/cncr.27581, PMID: - DOI - PMC - PubMed

LinkOut - more resources